Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Originally published as JCO Early Release 10.1200/JCO.2006.06.5664 on November 20 2006

Journal of Clinical Oncology, Vol 24, No 36 (December 20), 2006: pp. 5652-5657
© 2006 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haffty, B. G.
Right arrow Articles by Toppmeyer, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haffty, B. G.
Right arrow Articles by Toppmeyer, D.
Related Articles
Right arrowRelated Correspondence

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

Bruce G. Haffty, Qifeng Yang, Michael Reiss, Thomas Kearney, Susan A. Higgins, Joanne Weidhaas, Lyndsay Harris, Willam Hait, Deborah Toppmeyer

From the Departments of Radiation Oncology, Medical Oncology, and Surgery, Cancer Institute of New Jersey, Robert Wood Johnson Medical School–University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; and Department of Therapeutic Radiology and Section of Medical Oncology, Yale University School of Medicine, New Haven, CT

Address reprint requests to Bruce G. Haffty, MD, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, 195 Little Albany St, New Brunswick, NJ 08903-2681; e-mail: hafftybg{at}umdnj.edu

PURPOSE: To determine the prognostic significance of triple negative breast cancers with respect to locoregional relapse and distant metastasis in conservatively managed breast cancer patients.

PATIENTS AND METHODS: A database of conservative managed (conservative surgery followed by radiation) patients, in whom all three markers (estrogen receptor, progesterone receptor, and HER2/neu) were available, was reviewed. Patients were classified as triple negative if they tested negative for all three markers. Of 482 patients with all three markers available, 117 were classified as triple negative.

RESULTS: As of September 2005, with a median follow-up time of 7.9 years, of the 482 patients in the study, there have been 53 in-breast relapses, 10 nodal relapses, 77 distant relapses, and 69 deaths. At 5 years, the triple negative cohort had a poorer distant metastasis-free rate compared with the other subtypes (67% v 82%, respectively; P = .002). Triple negative subtype was an independent predictor of distant metastasis (hazard ratio = 2.14; 95% CI, 1.31 to 3.53; P = .002) and cause-specific survival (hazard ratio = 1.79; 95% CI, 1.03 to 3.22; P = .047). There was no significant difference in local control between the triple negative and other subtypes (83% v 83%, respectively). Of 99 BRCA-tested patients in this cohort, 10 had deleterious mutations in BRCA1, and seven had mutations in BRCA2. Of 10 BRCA1 patients, eight were triple negative, whereas only one of seven BRCA2 patients was triple negative (P < .001).

CONCLUSION: Patients classified as triple negative have a poor prognosis. However, there was no evidence that these patients are at higher risk for local relapse after conservative surgery and radiation. Patients with BRCA1 mutations develop predominantly triple negative tumors.

published online ahead of print at www.jco.org on November 20, 2006.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Correspondence

  • Potential Chemotherapy Options in the Triple Negative Subtype of Breast Cancer
    Kadri Altundag, Hakan Harputluoglu, Sercan Aksoy, and Ibrahim H. Gullu
    JCO 2007 25: 1294-1295 [Full Text]


This article has been cited by other articles:


Home page
Ann OncolHome page
S. L. Hines, L. A. Vallow, W. W. Tan, R. B. McNeil, E. A. Perez, and A. Jain
Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer
Ann. Onc., June 5, 2008; (2008) mdn283v1.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. A. Rakha, J. S. Reis-Filho, and I. O. Ellis
Basal-Like Breast Cancer: A Critical Review
J. Clin. Oncol., May 20, 2008; 26(15): 2568 - 2581.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. L. Nguyen, A. G. Taghian, M. S. Katz, A. Niemierko, R. F. Abi Raad, W. L. Boon, J. R. Bellon, J. S. Wong, B. L. Smith, and J. R. Harris
Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy
J. Clin. Oncol., May 10, 2008; 26(14): 2373 - 2378.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
E Korsching, S S Jeffrey, W Meinerz, T Decker, W Boecker, and H Buerger
Basal carcinoma of the breast revisited: an old entity with new interpretations
J. Clin. Pathol., May 1, 2008; 61(5): 553 - 560.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
Y. Eralp, D. Derin, Y. Ozluk, E. Yavuz, N. Guney, P. Saip, M. Muslumanoglu, A. Igci, S. Kucucuk, M. Dincer, et al.
MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer
Ann. Onc., April 1, 2008; 19(4): 669 - 674.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Kyndi, F. B. Sorensen, H. Knudsen, M. Overgaard, H. M. Nielsen, and J. Overgaard
Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group
J. Clin. Oncol., March 20, 2008; 26(9): 1419 - 1426.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Liedtke, C. Mazouni, K. R. Hess, F. Andre, A. Tordai, J. A. Mejia, W. F. Symmans, A. M. Gonzalez-Angulo, B. Hennessy, M. Green, et al.
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
J. Clin. Oncol., March 10, 2008; 26(8): 1275 - 1281.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. C.U. Cheang, D. Voduc, C. Bajdik, S. Leung, S. McKinney, S. K. Chia, C. M. Perou, and T. O. Nielsen
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
Clin. Cancer Res., March 1, 2008; 14(5): 1368 - 1376.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
E. J. Wasserman and A. R. Tan
Evolving Strategies for the Treatment of "Triple-Negative" Breast Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 120 - 126.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J.-H. Chen, R. S. Mehta, P. M. Carpenter, O. Nalcioglu, and M.-Y. Su
Magnetic Resonance Imaging in Predicting Pathological Response of Triple Negative Breast Cancer Following Neoadjuvant Chemotherapy
J. Clin. Oncol., December 10, 2007; 25(35): 5667 - 5669.
[Full Text] [PDF]


Home page
Ann OncolHome page
J.-H. Chen, G. Agrawal, B. Feig, H.-M. Baek, P. M. Carpenter, R. S. Mehta, O. Nalcioglu, and M.-Y. Su
Triple-negative breast cancer: MRI features in 29 patients
Ann. Onc., December 1, 2007; 18(12): 2042 - 2043.
[Full Text] [PDF]


Home page
JCOHome page
E. S. Thomas, H. L. Gomez, R. K. Li, H.-C. Chung, L. E. Fein, V. F. Chan, J. Jassem, X. B. Pivot, J. V. Klimovsky, F. H. de Mendoza, et al.
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
J. Clin. Oncol., November 20, 2007; 25(33): 5210 - 5217.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
C. U. Ihemelandu, L. D. Leffall Jr., R. L. Dewitty, T. J. Naab, H. M. Mezghebe, K. H. Makambi, L. Adams-Campbell, and W. A. Frederick
Molecular Breast Cancer Subtypes in Premenopausal African-American Women, Tumor Biologic Factors and Clinical Outcome
Ann. Surg. Oncol., October 1, 2007; 14(10): 2994 - 3003.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Harris, D. Toppmeyer, and B. G. Haffty
In Reply
J. Clin. Oncol., April 1, 2007; 25(10): 1295 - 1296.
[Full Text] [PDF]


Home page
JCOHome page
K. Altundag, H. Harputluoglu, S. Aksoy, and I. H. Gullu
Potential Chemotherapy Options in the Triple Negative Subtype of Breast Cancer
J. Clin. Oncol., April 1, 2007; 25(10): 1294 - 1295.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online